We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Targeted Therapy for Glomerulonephritis Using Arterial Delivery of Encapsulated Etanercept.
- Authors
Shushunova, Natalia A.; Mayorova, Oksana A.; Prikhozhdenko, Ekaterina S.; Goryacheva, Olga A.; Kulikov, Oleg A.; Plastun, Valentina O.; Gusliakova, Olga I.; Muslimov, Albert R.; Inozemtseva, Olga A.; Pyataev, Nikolay A.; Shirokov, Alexander A.; Gorin, Dmitry A.; Sukhorukov, Gleb B.; Sindeeva, Olga A.
- Abstract
Complex immunosuppressive therapy is prescribed in medical practice to patients with glomerulonephritis to help them overcome symptoms and prevent chronic renal failure. Such an approach requires long-term systemic administration of strong medications, which causes severe side effects. This work shows the efficiency of polymer capsule accumulation (2.8 ± 0.4 µm) containing labeled etanercept (100 μg per dose) in the kidneys of mice. The comparison of injection into the renal artery and tail vein shows the significant superiority of the intra-arterial administration strategy. The etanercept retention rate of 18% and 8% ID in kidneys was found 1 min and 1 h after injection, respectively. The capsules were predominantly localized in the glomeruli after injection in mice using a model of acute glomerulonephritis. Histological analysis confirmed a significant therapeutic effect only in animals with intra-arterial administration of microcapsules with etanercept. The proposed strategy combines endovascular surgery and the use of polymer microcapsules containing a high molecular weight drug that can be successfully applied to treat a wide range of kidney diseases associated with glomerular pathology.
- Subjects
GLOMERULONEPHRITIS; ETANERCEPT; CHRONIC kidney failure; MEDICAL practice; ENDOVASCULAR surgery; RENAL artery
- Publication
International Journal of Molecular Sciences, 2023, Vol 24, Issue 3, p2784
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms24032784